In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
This is worth keeping it mind as it may result in the next two quarters Zepbound revenue being misleading for projecting out
The Carnivore Bro, the Wellness Girlie, and the Discord Gamer all need different totems
Anal Biochem 174:575579 Bahar B, Tuncel AF, Holmes EW, Holmes DT (2017) An interactive website for analytical method comparison and bias estimation
Will I regain weight after stopping either medication